A case of pituitary stalk interruption syndrome with intermittent seizures as the first presentation

Juan Li, Hongwei Jia, Anindita Chakraborty, Zhihong Gao
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China

Correspondence to: Zhihong Gao
Department of Endocrinology and Metabolism
Tianjin Medical University General Hospital
No. 154 Anshan Road, Heping District, Tianjin, 300052, China.
tel: +13512997643; e-mail: zhihgao2014@163.com

Submitted: 2016-04-05 Accepted: 2016-08-09 Published online: 2016-11-18

Key words: pituitary stalk interruption syndrome; hypopituitarism; hyponatremia; seizures; growth hormone deficiency

Abstract
Pituitary stalk interruption syndrome (PSIS) is a congenital disease with isolated growth hormone deficiency (GHD) or multiple anterior pituitary hormone deficiencies (MPHD). The typical clinical manifestations of PSIS are growth retardation, hypoglycemia or delayed pubertal development. However, few reports showed cases of PSIS were diagnosed with acute epileptic seizures accompanied by hyponatremia. Here, we report an 18-year-old female presenting with episodes of intermittent seizures for 13 years. The electrolyte examination on many occasions has shown hyponatremia, even as low as 99.9 mmol/L. However, the cause of hyponatremia has not been further discussed. The patient had short stature and no pubertal development. The laboratory tests revealed growth hormone deficiency, secondary adrenal insufficiency, hypothyroidism and hypogonadotropic hypogonadism. MRI showed an ectopic hyperintense signal of the posterior pituitary and no visible anterior pituitary gland or stalk. The hormone replacement therapy helped to raise the sodium concentration to a normal level and in the termination of seizures.

INTRODUCTION
PSIS is typically characterized by a triad of interrupted pituitary stalk, absent or ectopic posterior pituitary and anterior pituitary hypoplasia or aplasia (Pinto et al. 1997). It was first reported by Fujisawa et al. (1987) in 1987. The estimated incidence of PSIS is approximately 0.5/100,000 births (El et al. 2011). PSIS has gained attention especially with the development of magnetic resonance imaging (MRI). Nevertheless, we still lack adequate understanding of this disease. PSIS critically affects the patients’ growth and development as well as the quality of life owing to the significantly high delayed diagnosis rate. The case we are presenting here had frequent seizures with severe hyponatremia and a delay of 13 years have been made in the diagnosis of PSIS.

MATERIAL AND METHODS

History of illness
The patient, a 18-years-old girl, was admitted to our hospital due to repeated seizure attack for 13 years, growth and developmental delay for 11 years. When she was 5 years old, the patient suffered from generalized tonic-clonic seizures accompanied by hyponatremia in the course of
respiratory tract infections. The symptoms relieved after correcting the electrolyte imbalance. Since then the patient experienced similar symptoms intermittently, especially accompanied with infection. The most frequent attacks were at an hour interval lasting from one minute to up to 20 minutes. Although the patient's health improved by correcting the sodium imbalance and with antiepileptic treatment, what exactly was causing the hypotension was never further discussed.

Seven years ago, she went to the local hospital presenting with delayed growth and development. She was 116 cm in height and weighted 16.5 kg with no signs of sexual maturation as a 11-year-old girl. Laboratory investigations found, serum total triiodothyronine was 0.84 ng/ml (normal range, 0.87–1.78), total thyroxine 2.09 ng/ml (range, 6.09–12.23) and thyroid-stimulating hormone (TSH) 5.76 μIU/ml (range, 0.34–5.06). Growth hormone (GH) was 0.006 ng/ml (range, 0.82–5.86). With the GH stimulation test, the peak GH value was less than 5 ng/ml. On head MRI, pituitary height was 3 mm and pituitary area was visible along T1 signal. She was diagnosed with hypothryoidism and growth hormone deficiency thus given levothyroxine and growth hormone replacement therapy as the treatment. Three months after the treatment with injections of growth hormone, she developed facial swelling, so the medication was stopped. Levothyroxine was stopped after six months due to patient's unwillingness to take medicine. To date, she still has neither achieved menarche nor developed secondary sexual characteristics. Her intellectual development had fallen behind her peers. The annual increase in height was less than 3 cm and showed no growth spurt.

Twenty days ago, the patient experienced an acute respiratory tract infection along with nausea and vomiting. She was diagnosed with “bacterial infection” which improved slightly after antibiotics treatment. Seven days ago, the patient suffered from an episode of seizure leading to unconsciousness accompanied with eye rolling, frothing and limb stiffness. The symptoms lasted for about one minute and the patient regained consciousness. So she was taken to local emergency department where the laboratory examination showed serum sodium was 105.7 mmol/L. After intravenous sodium supplementation for five days, serum sodium level increased to 127.3 mmol/L. She was referred to our hospital for further diagnosis and treatment.

**Past history**

The patient was born by a normal delivery and her birth weight was 3 kg. She had no history of the neonatal hypoxaemia or neonatal jaundice.

**Familial history**

Her father is 177 cm and weighs 75 kg. He started shaving at age 15. Her mother is 167 cm and weighs 55 kg. She attained menarche at age 18. Her sister is 170 cm and weighs 48 kg. She attained menarche at age 14. The patient had no other significant past medical history including history of trauma.

**Laboratory and imaging examination**

Laboratory tests showed serum cortisol was 2.16 μg/dl (range, 5–25) and serum adrenocorticotropic hormone (ACTH) 20.2 pg/ml (range, 0–46). Serum free triiodothyronine (FT3) was 1.74 pmol/l (range, 3.5–6.5), free thyroxine (FT4) 3.95 pmol/l (range, 11.5–23.5) and thyroid-stimulating hormone (TSH) 5.119 μIU/mL (range, 0.3–5.0). The thyroglobulin antibody and thyroid peroxidase antibody were negative. Serum follicle-stimulating hormone (FSH) was less than 0.30 IU/L (range, 2.5–10.2), luteinizing hormone (LH) less than 0.07 IU/L (range, 1.9–12.5) and the gonadotrophin-releasing hormone (GnRH) stimulation test revealed the LH secretion curve was low and flat and the peak median value of LH was less than 0.07 IU/L. The serum GH level was 0.05 ng/ml (range, 0.06–5), IGF-1 26.7 ng/ml (range, 111–996) and IGF-BP3 0.56 μg/ml (range, 2.4–10). Arginine stimulating GH test revealed all times of GH were less than 0.05 ng/ml and the complete growth hormone deficiency (GHD) was diagnosed. Her 24-hour urine volume was 1,200 ml and serum and urine osmolality were 293 mOsm/(kg.H2O) (range, 275–305) and 670 mOsm/(kg.H2O) (range, 600–1,000) respectively. Her skeletal development was delayed by 8.5 years with respect to her chronological age as shown in the X-ray. Pituitary MRI confirmed the diagnosis of PSIS, showing no visible anterior pituitary and pituitary stalk and an ectopic hyperintense signal of the posterior pituitary (Figure 1).

**Physical examination**

A physical examination showed that her temperature was 35.5°C, pulse 66/min and blood pressure 70/40 mmHg. On anthropometric measurements height was 135 cm, upper body segment to lower body segment 0.93, weight 25 kg and body mass index 13.72 kg/m². She was apathetic and showed poorly developed stature and severely undernourished appearance with a pale complexion. She had sparse eyebrows, absent pubic and axillary hair, hypoplasia of the mammary glands.
all well-being improved and had a good appetite. The blood pressure remained steady at 100/60 mmHg and the sodium level within 142–145 mmol/l. Later, she was treated with levothyroxine replacement therapy and thus her general condition improved. She did not receive growth hormone replacement and no gene testing was done given her low socio-economic status. She received follow-up treatment in our outpatient for the sex hormone replacement therapy.

**DISCUSSION**

As previously reported, PSIS was a male predominant disease and male-to-female ratio appeared 2.3–6.9:1 (Guo et al. 2013). The age for diagnosis of PSIS obviously showed differences among various studies. Wang et al. (2015) reported 74 patients of PSIS and the age at diagnosis was on an average 25 years which was apparently more than the age stated in other reports. To some extent, the reason resulting in delayed diagnosis was still the lack of sufficient understanding of this disease. To date, the underlying mechanisms of PSIS have remained unclear. Classically, it was thought that perinatal injury (such as breech presentation, dystocia and neonatal asphyxia) to the pituitary stalk was the primary cause. Afterwards, some scholars proposed that PSIS was associated with several midline defects and cerebral malformations (such as Arnold Chiari syndrome, microcephaly and cerebellar or corpus callosum atrophy) and suggested that the disorder in the hypothalamic-pituitary axis during embryonic stage of development may have resulted in malposition of fetus. Therefore, PSIS might be the cause rather than result of delivery modes and/or neonatal hypoxemia (Pinto et al. 1997). But approximately half of the patients had no history of any perinatal injury. Recently, it has been put forward that PSIS was found to be associated with other midline defects during the embryonic period with mutations in critical genes for early pituitary development, such as HESX1, LHX4, SOX3, OTX2 and PROKR2 genes. Although this genetic aetiology is a notable issue, less than 5% of patients with PSIS have been detected with gene mutations until now (Yang et al. 2013; Bar et al. 2015). On one hand there is a possibility that most of the PSIS patients have not received the gene assessment and on the other hand that most of the genes associated with PSIS have not yet been discovered.

The common modes of presentations with PSIS were growth retardation, hypoglycemia or delayed pubertal development. However, few reports showed cases similar to this patient presenting with acute epileptic seizures with severe hyponatremia. This patient has been suffering from frequent onset of seizures since childhood. On many occasions the electrolyte examination showed hyponatremia in which the serum sodium had been even as low as 99.9 mmol/L. However, the cause of hyponatremia was never discussed further. The symptoms improved after correction of the sodium imbalance with hypertonic saline and antiepileptic treatment. Recently, Nigro et al. (2015) performed a prospective observational multicenter study and they found that acute epileptic seizures appeared in 5% of patients with severe hyponatremia. It implies that acute and severe hyponatremia could lead to seizures, which may be the sole clinical manifestation (Nardone et al. 2016). Although hyponatremia is very common and has significant clinical relevance, it still has received little consideration. There are several causes of hyponatremia, such as excessive use of diuretics, vomiting, diarrhea, intake of excessive water and so on. But the most over-

**Fig. 1.** Pituitary magnetic resonance imaging. A. The sagittal slice shows no visible anterior pituitary. There is an ectopic posterior pituitary at the level of the median eminence with an invisible pituitary stalk. B. The coronal slice shows an invisible pituitary stalk.
looked reason is adrenocortical insufficiency, which is of grave importance as well as alarming. Our patient experienced frequent seizures from childhood. She was admitted to the hospital where the laboratory examination showed hyponatremia. Sometimes she even experienced serious hypotension leading to shock. However, she never received the adrenal cortex function examination despite the symptoms. This is the first reason of a delayed diagnosis. Hence, as suggested by Wójcik et al. (2013), multiple pituitary hormone deficiencies must be considered in the prepubertal patients presenting with severe hyponatremia.

Seven years ago, the patient went to the same hospital for further treatment due to her delayed growth and development. Although the growth hormone test showed GH was below normal level, yet the residual pituitary functions have not been evaluated aptly. This is the second important reason for the delay in diagnosis. It is well established that, GH has a close connection with hypothalamus and pituitary. Whether it is the congenital aplasia or acquired tumors or any inflammatory causes, it could result in GHD. For example, PSIS is one of the causes of the GHD. Kyriacou et al. (2010) evaluated 23 patients with idiopathic GHD by cranial MRI and found that 46% of the patients had PSIS. Moreover, several large reports of PSIS had shown that the incidence of growth hormone deficiency was 100% (Pham et al. 2013; Guo et al. 2013; Wang et al. 2015). Therefore, the patients accompanied with short stature or GHD should be considered to take cranial MRI examination to exclude PSIS. Besides, an early diagnosis and treatment of PSIS can prevent the patient from developing a permanent short stature (Tauber et al. 2005).

Furthermore, the patient should have been diagnosed with secondary hypothyroidism because there was a very low serum thyroxine with a normal TSH level seven years ago, a slip leading to the third reason for a delayed diagnosis. It puts emphasis on the fact that when hypothyroidism is diagnosed clinically, it is very essential to distinguish its type whether primary or secondary. If it raises suspicion of the secondary causes then the residual pituitary functions should be screened. When insufficiency of adrenal cortical function exists simultaneously with secondary hypothyroidism, the replacement of the adrenocortical hormone should be done prior to the supplementation of thyroid hormone.

The patient presented with hyponatremia, hypothyroidism and growth hormone deficiency. Amongst these, the hypothalamus or pituitary abnormality was the most significant cause for suspicion. The MRI report done 7 years ago showed pituitary height was 3mm, visible pituitary area along T1 signal and an undescribed the pituitary stalk or neurohypophysis. Nonetheless, this may be another reason for the delay in diagnosis ‘of the case’ as PSIS. MRI is a gold standard in the diagnosis of PSIS and the ectopic posterior pituitary is the hallmark of the disease (Vijayanand et al. 2007).

Bar et al. (2015) followed 21 PSIS patients with growth retardation ranging from 7.3 to 16.6 years and documented a progressive worsening of the endocrine impairment. Therefore, the regular assessment of pituitary function and long-term follow-up for PSIS patients are very essential.

REFERENCES